We have launched 4 self-developed monoclonal antꩲibody (mAb) biosimilars including the first Chinese biosimilar 汉利康® (rituximab), the first Chinese mAb biosimilar entering both China and the EU market 汉曲优® (trastuzumab)ꦉ and , 汉达远® (adalimumab), and 汉贝泰® (bevacizumab), navigating at the forefront of Chinese biopharmaceutical industry.
Fully leveraging the global research and development platform, we have been exploring pipeline opportunities for more than 20 innovative mAb cand🐓idates, with significant potential for a variety of PD-1-based immuno-oncology combination therapies.
We have 3 manufacturing facilities, namely Xuhui Facility, Songjiang First Plant and Songjiang Second Plant. Our commercial capacity totals 48,000L for now with an estimate of 144,000L in 2026. Xuhui Fac🍸ility is certificated by China and the EU Good Manufacturing Practice💖 (GMP). Songjiang First Plant is certificated by China GMP and the EU QP.
We have built an in-house commercial team focused on domestic market, covering marketing, access, channel, pricing, strategy and sales and compromising of about 450 pro🌠fessionals; we have also 🔯joined forces with oversea partners, expanding our reach in major markets as well as emerging markets worldwide.
